Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016.
Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016. Chris Seward cseward@newsobserver.com
Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016. Chris Seward cseward@newsobserver.com

GSK emerges with smaller, more focused NC presence

June 12, 2015 06:22 PM